[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:digestive-system-neuroendocrine-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":24,"states":25},"Digestive System Neuroendocrine Neoplasm",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06788938","Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms",[12],"Phase 2","RECRUITING","2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.447902Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07661420","211At-MABG in Adults With Advanced Neuroendocrine Cancers",[20],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:57.705506Z","2026-07-05T03:45:20.260334Z",[],[]]